School of Medicine
Showing 1-10 of 286 Results
-
David Maahs
Professor of Pediatrics (Endocrinology) at the Lucile Salter Packard Children's Hospital and at the Stanford University Medical Center
Bio In 2016 I moved to become Professor of Pediatrics and Division Chief of Pediatric Endocrinology at Stanford University. My research interest is to improve care and prevent complications in people with type 1 diabetes (T1D). I was co-author with Dr Peter Chase on the 12th and 13th editions of Understanding Diabetes, or Pink Panther education books. Specifically, my research has extended from epidemiologic studies identifying targets to development of clinical trials to test interventions. My NIDDK sponsored K23 “Cardiovascular Disease in Type 1 Diabetes Mellitus: Young Adults to Adolescents” focused on cardiovascular and kidney complications in young adults with T1D. I continued this work as part of the Coronary Artery Calcification in Type 1 Diabetes (CACTI) Study with Drs. Marian Rewers and Janet Snell-Bergeon and in the pediatric population with Dr. Paul Wadwa and as investigator with the Search for Diabetes in Youth study. I am a past co-Chair for Protocols and Publications with the Type 1 Diabetes Exchange and continue as a Steering Committee member and director of international collaborations which complements my role as Secretary-General for ISPAD. While in Colorado I was local PI on PERL, an RCT to prevent early kidney function decline with Drs Michael Mauer (UMinnesota) and Alessandro Doria (Joslin) as PIs. I am a PI on FL3X, an innovative behavioral intervention for adolescents with T1D with Drs. Elizabeth Mayer-Davis (UNC) and Michael Seid (Cincinnati). As a logical extension of this research to prevent T1D complications, my research has increasingly focused on the development of the artificial pancreas as improved glucose control is the best proven method to prevent T1D complications. In Colorado I was the local PI on 3 UC4 funded artificial pancreas studies and I continue this research at Stanford with Drs Bruce Buckingham and Korey Hood. I work with clinical and engineering collaborators at RPI, JAEB, Sansum/UCSB, Yale, UVa, Cambridge, Boston University, and UC-Boulder on JDRF, NIDDK, and NSF funded studies as listed below. I was co-PI with Dr. Klingensmith on the Barbara Davis Center T32 and K12 training grants in Pediatric Endocrinology. I am Associate Director of the Stanford University Diabetes Research Center with Drs Seung Kim (Director) and Frederic Kraemer https://sdrc.stanford.edu .
-
Alex Macario MD MBA
Professor of Anesthesiology, Perioperative and Pain Medicine and, by courtesy, of Health Research and Policy at the Stanford University Medical Center
Current Research and Scholarly Interests Dr. Macario studies health care economics & outcomes, with a special focus on surgery and anesthesia. He is well known for helping develop the field of operating room management, and is keenly interested in the cost-effectiveness analyses of drugs and devices. For the past decade Dr. Macario has added medical education as a research priority to better understand methods to best teach students and residents. Google Scholar calculates Dr. Macario’s H-Index as 45 and his I-10 as 99.
-
M Bruce MacIver
Professor (Research) of Anesthesiology, Perioperative and Pain Medicine
Current Research and Scholarly Interests We study drug effects on the nervous system. Cellular, synaptic and molecular drug actions are investigated using electrophysiological and pharmacological tools in cortical/hippocampal brain slice preparations. We are also interested in mechanisms of neuronal integration and synchronization, especially related to patterns of EEG activity seen in vivo and in brain slices.
-
Crystal Mackall
Professor of Pediatrics (Hematology/Oncology) and of Medicine
Current Research and Scholarly Interests Recent clinical studies, by us and others, have demonstrated that T cell based immunotherapy can eradicate cancers resistant to all other available therapies. Our program is focused on using genetically engineered T cells to treat cancer. We link the bench with the bedside, developing novel therapies for early phase testing in clinical trials, will simultaneously conducting intensive studies on clinical samples obtained from patients treated on immunotherapy trials.